ACTIVE+
- EFFECTIVENESS AND SAFETY OF I+V TREATMENT IN PATIENTS WITH CLL
- RETROSPECTIVE STUDY OF OUTCOMES IN TP53 MUTATED AND/OR DELETED CLL TREATED WITH CHEMOTHERAPY-FREE FRONTLINE TARGETED THERAPIES
TP53 disruption is well recognized as an adverse prognostic factor in the setting of conventional chemotherapy and fixed duration venetoclax-based therapy but its prognostic significance for patients receiving continuous targeted treatment in the frontline is not fully established. In order to address this issue, ERIC is conducting a retrospective multicenter study of real-world clinical outcomes of TP53 mutated and/or deleted CLL treated with chemotherapy-free frontline targeted therapies, particularly focusing on continuous treatment. The study is coordinated by Sunil Iyengar (London, UK). - CLINICAL SIGNIFICANCE AND TREATMENT OUTCOMES OF ACCELERATED CHRONIC LYMPHOCYTIC LEUKEMIAS
The aim of this project is studying the prevalence, clinical significance and treatment outcomes of accelerated chronic lymphocytic leukemia. - CLONAL RELATIONSHIP IN RICHTER TRANSFORMATION (RT)
Riccardo Moia (Novara, Italy) launched an ERIC project aiming at studying biological and clinical features of RT stratified on their clonal relationship with the preceding CLL. - CLINICAL OUTCOMES OF PATIENTS WITH CLL BELONGING TO SUBSET #2
This observational retrospective study aims to study the clinical outcomes of patients with CLL belonging to subset #2, focusing on novel agents. - CLINICAL IMPORTANCE OF SATELLITE SUBSETS
This is an observational retrospective study aiming to study the clinical importance of satellite subsets to major stereotyped subsets, i.e., subsets #1,#2, and #8 in chronic lymphocytic leukemia. Major stereotyped subsets bear
striking immunogenetic similarities to some minor subsets, which have been termed satellite subsets. Typical pairs of major and satellite subsets include (i)#1 and #99; (ii) #2 and #169, and (ii) #8 and #8B. Despite the immunogenetic similarities, the clinical associations between these pairs of major and satellite subsets are largely unknown and represent the focus of this study. - IMMUNOGLOBULIN GENE SEQUENCE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ERA OF NGS: PROGNOSTIC IMPLICATIONS
This retrospective study will be a collaborative effort towards the detailed immunogenetic analysis of immunoglobulin gene sequence data obtained through next generation sequencing (NGS), aiming to:- explore the clinical relevance of the 98% cut-off value for IGHV gene identity to the germline for discriminating patients into U-CLL and M-CLL categories based on results obtained by NGS
- assess the clinical implications of co-existing clonotypes bearing discordant IGHV gene SHM status
- evaluate the clinical relevance of intraclonal diversification within the dominant clonotype
- search for a reliable cut-off value for distinguishing between secondary CLL-like clonal expansions, immune reactive cell clones, and the normal background’
- RESOLVE TRIAL: AN INTERNATIONAL, MULTI-CENTER, RANDOMIZED, CONTROLLED PRAGMATIC CLINICAL TRIAL
Acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) are among the most common forms of blood cancer in adults. Depending on the stage of the disease, patients receive chemotherapy, immunotherapy or a stem cell transplant. The diagnostic test “measurable residual disease” (MRD) can be used early on in the course of treatment to determine whether the leukemia is responding very well to treatment. MRD is detectable when very sensitive diagnostic methods such as flow cytometry still detect leukemia cells in the body that cannot be detected with more traditional methods like the microscope. The RESOLVE research network consists of 21 partners from 8 countries, who will establish MRD as a personalized diagnostic tool, which will serve as a guideline for personalized treatment recommendations.
- PREDICTIVE VALUE OF CK IN CLL PATIENTS TREATED WITH TARGETED THERAPIES
This is a multicentric restrospective study aiming to assess the prognostic and predictive relevance of complex karyotype in CLL patients treated with targeted therapies (BTK or BCL2 inhibitors) on real-world evidence and clinical trials data. - INFECTIONS IN THE ERA OF NEW TARGETED CLL THERAPIES
Elzbieta Kalicinska (Wrocław, Poland) launched an ERIC project to compare the cumulative incidence of severe infections (G3-G5) in CLL patients treated with regimens based on venetoclax or second-generation BTKs in the first and subsequent lines of treatment (R/R setting).
COMPLETED+
- EVALUATION OF THE DIFFERENTIAL IMPACT OF VENETOCLAX AND VENETOCLAX-BASED COMBINATION REGIMENS ON PRE-EXISTING AND TREATMENT-EMERGENT AUTOIMMUNE CYTOPENIAS IN PATIENTS WITH CLL
- CENTRAL NERVOUS SYSTEM CLL, A RARE DISEASE WITH UNCLEAR MANAGEMENT
- CD-19-CAR-T CELLS IN PATIENTS WITH RICHTER’S TRANSFORMATION (RT)
- CARDIAC FUNCTION ASSESSMENT IN PATIENTS WITH CLL
- OBINUTUZUMAB + CHLORAMBUCIL AS FRONT-LINE TREATMENT IN CLL
- OBSERVATIONAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF BENDAMUSTINE PLUS RITUXIMAB IN PATIENTS AFFECTED BY CLL
- PROGNOSTIC AND PREDICTIVE VALUE OF COMPLEX KARYOTYPING USING CHROMOSOME BANDING ANALYSIS OR MICROARRAY-BASED PROFILING IN CLL
- COMPARATIVE ANALYSIS OF TARGET ENRICHMENT TECHNIQUES FOR THE DETECTION OF GENE MUTATIONS IN CLL
- COVID-19 SEVERITY AND MORTALITY IN PATIENTS WITH CLL
- COVID-19 SEVERITY AND MORTALITY IN PATIENTS WITH CLL: AN UPDATE OF THE INTERNATIONAL ERIC AND CAMPUS CLL STUDY
- THROMBOTIC AND BLEEDING COMPLICATIONS IN PATIENTS WITH CLL AND SEVERE COVID-19
- THE EVOLVING LANDSCAPE OF COVID-19 AND POST-COVID CONDITION IN PATIENTS WITH CLL
- OTHER MALIGNANCIES IN THE HISTORY OF CLL: AN INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL, IN HARMONY
- REAL-WORLD EVIDENCE ON THERAPEUTIC STRATEGIES AND TREATMENT-SEQUENCING IN PATIENTS WITH CLL
DATABASES+
- TP53 VARIANTS DATABASE IN CLL
The TP53 variants database collects the list of curated TP53 variants obtained within certified TP53 diagnostics with the aim of providing a tool to facilitate the interpretation of TP53 variants in Chronic Lymphocytic Leukemia (CLL). The main objectives of the TP53 variants database are:
[1] to create a CLL-specific database of TP53 variants, perform expert curation and interpretation, and make the molecular TP53 data available to the scientific community
[2] to determine the profile of TP53 variants detected in CLL
[3] to analyze TP53 variant profiles in the context of different clinical and biological variables in connection with data from the ERIC CLL database - ERIC CLL database
The ERIC CLL database is a data management system for the collection and organization of prospective and retrospective clinical and biological data from patients with Chronic Lymphocytic Leukemia (CLL). The main objectives of the ERIC CLL database are:
[1] to collect and transform clinically relevant RWD into evidence and correlate with biological data in order to provide accurate information about the state-of-the-art diagnosis
[2] to generate hypotheses regarding important disease characteristics, laboratory studies and therapies
[3] to define relevant parameters influencing CLL impact on health systems - ERIC IG CLL database
The ERIC CLL Immunogenetics database (CLL-DB, hosted by the International Immunogenetics Information System – IMGT) contains immunogenetic data from patients with CLL aiming to foster high-quality collaborative research on CLL and related disorders, with a main focus on understanding the biology of CLL and refining the molecular stratification of patients.
COMPLETED PROJECTS
- Identification and characterization of major stereotyped subsets in cll
- Clinical relevance of major stereotyped subsets in CLL
- Clinical significance of stereotyped subset #2
- ERIC recommendations for IG gene analysis in CLL
- Satellite stereotyped subsets and their prognostic relevance
ACTIVE PROJECTS
- Large-scale analysis of BCR stereotypy in CLL – the 100,000 cohort
- In-depth study of satellite stereotyped subsets – focus on clinical significance
- Dissecting the heterogeneity of IG-mutated CLL
- NGS Immunogenetics in the era of novel agents